Quantisnow Logo
Dashboard

Protalix BioTherapeutics to Announce Fiscal Year 2023 Financial and Business Results on March 14, 2024

$PLX
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $PLX alert in real time by email

Company to host conference call and webcast at 8:30 a.m. EDT

CARMIEL, Israel, March 7, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2023 and provide a business update on Thursday, March 14, 2024.

Protalix Biotherapeutics Logo

Management will host a conference call with investors to discuss the financial results and provide a business update.

Conference Call Details:

Date:                            Thursday, March 14, 2024

Time:                            8:30 a.m. Eastern Daylight Time (EDT)

Toll Free:                     1-877-423-9813

International:              1-201-689-8573

Israeli Toll Free:          1-809-406-247

Conference ID:            13744193

Call me™:                    https://tinyurl.com/4pkhcxcj

The Call me™ feature allows you to avoid the wait for an operator; you enter your phone number on the platform and the system calls you right away.

Webcast Details: 

Company Link:            https://protalixbiotherapeutics.gcs-web.com/events0

Webcast Link:              https://tinyurl.com/mumnf9da

Conference ID:            13744193

Participants are requested to access the call at least 15 minutes ahead of the conference to register, download and install any necessary audio software. A replay of the call will be available for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.

Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others.

Investor Contact

Mike Moyer, Managing Director

LifeSci Advisors

+1-617-308-4306

mmoyer@lifesciadvisors.com 

Logo - https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

Cision View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-announce-fiscal-year-2023-financial-and-business-results-on-march-14-2024-302082682.html

SOURCE Protalix BioTherapeutics, Inc.

Get the next $PLX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PLX

DatePrice TargetRatingAnalyst
More analyst ratings

$PLX
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

    CARMIEL, Israel, March 24, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that its management will be participating in the iAccess Alpha Virtual Best Ideas Spring Investment Conference 2025, to be held virtually March 25-26, 2025. iAccess Alpha hosts virtual investor conferences featuring companies recommended by investors. These two-day events include webcast presentations on Day 1, followed by one-on-one meetings between Protalix management a

    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

    Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update.     "2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer and Brazil," said Dror Bashan, Protalix's Presi

    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

    Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2024 and provide a business and clinical update on March 17, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Detai

    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PLX
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PLX
 Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PLX
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PLX
 SEC Filings

See more

$PLX
 Leadership Updates

Live Leadership Updates

See more

  • Levicept Appoints Eliot Forster as CEO

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

  • Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

    Appointment effective as of September 14, 2023;Zeev Bronfeld to retire from the Board of Directors CARMIEL, Israel, Sept. 12, 2023 /PRNewswire / Protalix BioTherapeutics, Inc. (NYSE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that the Company's Board of Directors has appointed Eliot Richard Forster, Ph.D. to serve on the Board of Directors as its Chairman, effective as of September 14, 2023. In

    $IMTX
    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protalix BioTherapeutics Appoints Shmuel "Muli" Ben Zvi, Ph.D. to its Board of Directors

    CARMIEL, Israel, June 30, 2022 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE:PLX) (TASE: PLX), announced today that the Company's Board of Directors has appointed Shmuel "Muli" Ben Zvi, Ph.D. to serve on the Company's Board of Directors. In addition to Dr. Ben Zvi's appointment as an independent director, he was also appointed to serve on the Company's Audit Committee and Compensation Committee. "We are excited to have Muli join our Board of Directors," commented Zeev Bronfeld, Chairman of Protalix's Board of Directors. "He brings extensive financial and economic knowle

    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PLX
 Financials

Live finance-specific insights

See more

  • Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results

    Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2024, and provided a business and clinical update.     "2024 was a record year in revenues from selling goods for Protalix, as we experienced increases in all three of our revenue streams, Chiesi, Pfizer and Brazil," said Dror Bashan, Protalix's Presi

    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025

    Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, March 10, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the fiscal year ended December 31, 2024 and provide a business and clinical update on March 17, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Detai

    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

    Company to host conference call and webcast today at 8:30 a.m. EST CARMIEL, Israel, Nov. 14, 2024 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE-American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2024, and provided a business and clinical update. "We are pleased to report that all eight cohorts of our phase I first-in-human study of PRX-115, our recombinant uricase candidate being developed for the treatment of uncontrolled gout, are now complete,

    $PLX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$PLX
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more